Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir-containing combination therapy versus non-raltegravir combination therapy for reduction of proviral HIV DNA
2009-013679-23Phase 4Active
- Sponsor
- Stop Sida
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of raltegravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Stop Sida. Primary endpoints: Reduction of proviral HIV DNA at week 24 and Number of patients with undetectable proviral DNA under raltegravir. Started Nov 2009; status: active.
02
Drugs
raltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-013679-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013679-23.